NCT07189871 - 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)Ovarian CancerCervical CancerEndometrial CancerTNBC, Triple Negative Breast CancerSmall Cell Lung Cancer (SCLC )Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG

177Lu-BetaBart

BetaBart administered by intravenous (IV) infusion every 6 weeks